乌司他丁对脓毒症结局的影响：荟萃分析综述。

IF 3.2 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-03-06 DOI:10.1016/j.clinthera.2025.01.013

Sheng Cao PharmD, Ping Han PharmD

{"title":"乌司他丁对脓毒症结局的影响：荟萃分析综述。","authors":"Sheng Cao PharmD, Ping Han PharmD","doi":"10.1016/j.clinthera.2025.01.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Sepsis, a multifaceted disorder, emerges from dysregulated host response to infection, culminating in organ dysfunction and heightened risk of mortality. Present umbrella systematic review was conducted to impart accurate data regarding the effect of urinary trypsin inhibitor (UTI) alone, UTI in combination with thymosin α1, and UTI in combination with Xuebijing on sepsis and inflammation, 28-day mortality rate survival day, time of mechanical ventilation, length of intensive care unit stay, and acute physiology and chronic health evaluation (APACHE II) score.</div></div><div><h3>Methods</h3><div>Relevant studies were searched in international databases, including PubMed, Scopus, EMBASE, Web of Science, and Cochrane Central Library up to March 2024. Our study included meta-analyses that evaluated the effects of ulinastatin (UTI) alone, or in combination with thymosin α1 or Xuebijing, on sepsis and inflammatory biomarkers.</div></div><div><h3>Results</h3><div>Nine studies were deemed relevant and subsequently included in the study. The age of the study's participants was between 42.3 and 55.7 years. In total, the dose varied between 166 and 570 KIU/12 h. Moreover, the duration varied between 3 and 8.5 days.</div></div><div><h3>Conclusion</h3><div>A comprehensive assessment of ulinastatin's overall efficacy necessitates a careful consideration of the combined effects of ulinastatin with other interventions. Future research is warranted to disentangle the specific contributions of ulinastatin in combination therapies and to enhance our understanding of its independent effects in clinical settings.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 5","pages":"Pages 377-383"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect of Ulinastatin on Sepsis Outcomes: An Umbrella Review of Meta-Analysis\",\"authors\":\"Sheng Cao PharmD, Ping Han PharmD\",\"doi\":\"10.1016/j.clinthera.2025.01.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>Sepsis, a multifaceted disorder, emerges from dysregulated host response to infection, culminating in organ dysfunction and heightened risk of mortality. Present umbrella systematic review was conducted to impart accurate data regarding the effect of urinary trypsin inhibitor (UTI) alone, UTI in combination with thymosin α1, and UTI in combination with Xuebijing on sepsis and inflammation, 28-day mortality rate survival day, time of mechanical ventilation, length of intensive care unit stay, and acute physiology and chronic health evaluation (APACHE II) score.</div></div><div><h3>Methods</h3><div>Relevant studies were searched in international databases, including PubMed, Scopus, EMBASE, Web of Science, and Cochrane Central Library up to March 2024. Our study included meta-analyses that evaluated the effects of ulinastatin (UTI) alone, or in combination with thymosin α1 or Xuebijing, on sepsis and inflammatory biomarkers.</div></div><div><h3>Results</h3><div>Nine studies were deemed relevant and subsequently included in the study. The age of the study's participants was between 42.3 and 55.7 years. In total, the dose varied between 166 and 570 KIU/12 h. Moreover, the duration varied between 3 and 8.5 days.</div></div><div><h3>Conclusion</h3><div>A comprehensive assessment of ulinastatin's overall efficacy necessitates a careful consideration of the combined effects of ulinastatin with other interventions. Future research is warranted to disentangle the specific contributions of ulinastatin in combination therapies and to enhance our understanding of its independent effects in clinical settings.</div></div>\",\"PeriodicalId\":10699,\"journal\":{\"name\":\"Clinical therapeutics\",\"volume\":\"47 5\",\"pages\":\"Pages 377-383\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0149291825000141\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825000141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的：脓毒症是一种多方面的疾病，起源于宿主对感染的反应失调，最终导致器官功能障碍和死亡风险增加。本研究对尿胰蛋白酶抑制剂（UTI）单用、UTI联合胸腺素α1、UTI联合血痹净对脓毒症和炎症、28天死亡率生存日、机械通气时间、重症监护病房住院时间、急性生理和慢性健康评估（APACHE II）评分的影响进行了综合系统评价。方法：检索截至2024年3月的PubMed、Scopus、EMBASE、Web of Science、Cochrane Central Library等国际数据库的相关研究。我们的研究包括meta分析，评估乌司他丁（UTI）单独或与胸腺素α1或血必净联合使用对脓毒症和炎症生物标志物的影响。结果：9项研究被认为是相关的，并随后纳入研究。研究参与者的年龄在42.3岁到55.7岁之间。总的剂量在166 - 570 KIU/12 h之间，持续时间在3 - 8.5天之间。结论：全面评估乌司他丁的总体疗效需要仔细考虑乌司他丁与其他干预措施的联合作用。未来的研究有必要解开乌司他丁在联合治疗中的具体作用，并加强我们对其在临床环境中的独立作用的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Effect of Ulinastatin on Sepsis Outcomes: An Umbrella Review of Meta-Analysis

Objectives

Sepsis, a multifaceted disorder, emerges from dysregulated host response to infection, culminating in organ dysfunction and heightened risk of mortality. Present umbrella systematic review was conducted to impart accurate data regarding the effect of urinary trypsin inhibitor (UTI) alone, UTI in combination with thymosin α1, and UTI in combination with Xuebijing on sepsis and inflammation, 28-day mortality rate survival day, time of mechanical ventilation, length of intensive care unit stay, and acute physiology and chronic health evaluation (APACHE II) score.

Methods

Relevant studies were searched in international databases, including PubMed, Scopus, EMBASE, Web of Science, and Cochrane Central Library up to March 2024. Our study included meta-analyses that evaluated the effects of ulinastatin (UTI) alone, or in combination with thymosin α1 or Xuebijing, on sepsis and inflammatory biomarkers.

Results

Nine studies were deemed relevant and subsequently included in the study. The age of the study's participants was between 42.3 and 55.7 years. In total, the dose varied between 166 and 570 KIU/12 h. Moreover, the duration varied between 3 and 8.5 days.

Conclusion

A comprehensive assessment of ulinastatin's overall efficacy necessitates a careful consideration of the combined effects of ulinastatin with other interventions. Future research is warranted to disentangle the specific contributions of ulinastatin in combination therapies and to enhance our understanding of its independent effects in clinical settings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.